Eikon Therapeutics

This early-stage study aims to find a safe and effective dose of a new drug called EIK1005 for people with advanced solid tumors that have spread or cannot be removed by surgery. Researchers will test EIK1005 by itself and combined with an existing immunotherapy drug (pembrolizum…

This is the first study in people testing a new oral drug called IMP1734 for advanced solid tumors that have spread or returned. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also check if the drug helps shrink tumors in patients…

This study is testing if adding an experimental drug called EIK1001 to the standard first treatment (pembrolizumab) works better for controlling advanced melanoma. About 740 adults with newly diagnosed, advanced melanoma will receive either the new combination or the standard tre…

This study is testing whether adding an experimental drug called EIK1001 to standard chemotherapy and immunotherapy helps people with advanced lung cancer. It will involve about 70 adults with stage 4 non-small cell lung cancer who haven't had treatment for their advanced disease…